Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$13.37M$13.37M−45.7% vs Q3 2024 Net Income-$27.89M-$27.89MN/M vs Q3 2024 EPS Diluted-$0.47-$0.47N/M vs Q3 2024 Operating Income-$30,594,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$31,255,000N/M Margins · derivedOperating margin-228.9%−173.0 pt vs Q3 2024
Net margin-208.7%−172.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 10, 2025 · 41 d after period end